Develops and commercializes inhaled medicines, injectable treatments and insulin-delivery devices for people with diabetes, heart or kidney disease, and pulmonary hypertension.
10-K for FY2025, filed Feb 26, 2026We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on…View ↗
Our cardiometabolic business is currently comprised of three commercial products: Afrezza (insulin human) Inhalation Powder; Furoscix…View ↗
Afrezza is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza was developed by us…View ↗
Furoscix is a novel formulation of furosemide that delivers an 80 mg dose via an on-body infusor over a five-hour period. Furoscix is…View ↗
V-Go is a mechanical basal-bolus insulin delivery system that is worn like a patch and can eliminate the need for taking multiple daily…View ↗
The proprietary formulation and inhaler technologies used in Afrezza have also been deployed in our efforts to develop products to treat…View ↗
MannKind earns product revenue from sales of Afrezza, Furoscix and V-Go to wholesalers and specialty pharmacies, and from Tyvaso DPI supplies delivered to United Therapeutics. Collaboration arrangements bring in revenue for research and development services, while royalties are based on United Therapeutics' Tyvaso DPI net sales.
10-K for FY2025, filed Feb 26, 2026Amounts represent the revenue from Afrezza, Furoscix and V-Go sales to wholesalers and specialty pharmacies and from the manufacture of…View ↗
Amounts represent revenue generated from the Company’s collaboration arrangements, including Next-Gen R&D Services (as defined in Note 11)…View ↗
Amounts represent royalties earned based on UT’s net revenue from Tyvaso DPI sales.View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$349M
10-K for FY2025, filed Feb 26, 2026
$349M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product Revenue
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
62%
FY2022: 81%
|
Product Revenue, FY2025
$216.5M Sources
|
Sold outright |
|
Services
|
1.2%
FY2022: 3.1%
|
Services, FY2025
$4.3M Sources
|
|
|
Royalties
Licensed
10-K for FY2025, filed Feb 26, 2026 |
37%
FY2022: 16%
|
Royalties, FY2025
$128.1M Sources
|
Licensed |
Commercial products are sold through wholesale distributors, specialty and retail pharmacies, and durable medical equipment suppliers. MannKind commercializes Afrezza, Furoscix and V-Go itself in the U.S., works with regional partners outside it, and United Therapeutics commercializes Tyvaso DPI.
10-K for FY2025, filed Feb 26, 2026At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services…View ↗
In the United States, we are solely responsible for the commercialization of Afrezza, Furoscix and V-Go. Outside of the U.S., our strategy…View ↗
The proprietary formulation and inhaler technologies used in Afrezza have also been deployed in our efforts to develop products to treat…View ↗
10-K for FY2025, filed Feb 26, 2026
As of December 31, 2025 , there was a de minimis amount of allowance for credit losses and doubtful accounts for commercial accounts…View ↗
Yes. It kept 2 cents of every revenue dollar as net income in FY2025 and turned 4 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$23.2MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
Growing. Revenue grew 4.6x in 4 years, from $75.4M in FY2021 to $349M in FY2025, about 47% a year.
Furoscix joins the portfolio
MannKind's commercial portfolio moved beyond Afrezza and V-Go to include Furoscix, a furosemide treatment delivered through an on-body infusor.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026In our endocrine business unit, we currently commercialize two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting…View ↗
Afrezza in India
The older report described Cipla as conducting a study toward an Indian regulatory submission; the latest says MannKind sent Cipla an initial Afrezza shipment for an India launch.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026We are solely responsible for the commercialization of Afrezza and V-Go in the United States. Outside of the U.S., our strategy has been to…View ↗
In the United States, we are solely responsible for the commercialization of Afrezza, Furoscix and V-Go. Outside of the U.S., our strategy…View ↗
Competes with Eli Lilly and, Novo Nordisk, Sanofi, AstraZeneca, Abbott Laboratories, Amgen, Bayer, Bioheart, Boston Scientific, Boehringer Ingelheim, Corstasis, GlaxoSmithKline, Johnson & Johnson, Merck, Medtronic, Novartis, Pfizer, Roche, Sarfez Pharmaceuticals, and Servier Pharmaceuticals
10-K for FY2025, filed Feb 26, 2026Afrezza is administered at the beginning of a meal, so its principal competitors are “rapid-acting” insulin analogs that are used for…View ↗
Loading...